Search results
Showing 1831 to 1845 of 2026 results for nice guidelines
results from a new economic model developed specifically for the cannabis guideline. The model included data from all relevant trials,...
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .
NICE has developed a medtech innovation briefing (MIB) on cyanoacrylate glue for hernia mesh fixation .
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.
Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
Pneumonia (community-acquired): antimicrobial prescribing (NG138)
This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).
Respiratory tract infections (self-limiting): prescribing antibiotics (CG69)
We have withdrawn this guideline and incorporated the relevant recommendations from it into NICE's antimicrobial prescribing guidelines on sinusitis, sore throat, otitis media and cough.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or recently pregnant people (NG255).
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
Evidence-based recommendations on cemiplimab (Libtayo) for recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.